Edesa Biotech Inc EDSA
📋 Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2008-08-25 |
| Shares Out. | 9,630,000 |
| Website | edesabiotech.com/ ↗ |
| Phone | 19054751234 |
| Employees | 17 |
| Net Income | -$4.2M |
| Total Assets | $12.4M |
| Total Liabilities | $2.2M |
| Equity | $10.2M |
About Edesa Biotech Inc
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Edesa Biotech Inc is a publicly traded company under the ticker symbol EDSA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)